Atossa Therapeutics Showcases (Z)-Endoxifen Research at Conference
Atossa Therapeutics Highlights Innovative Cancer Research
SEATTLE — Atossa Therapeutics, Inc. (NASDAQ: ATOS), a pioneering clinical-stage biopharmaceutical company, proudly announces its participation at the upcoming American Association for Cancer Research (AACR) Special Conference focused on cancer research. The event takes place from December 9 to 11, featuring a significant presentation on (Z)-endoxifen, a compound with promising anti-cancer properties.
Understanding (Z)-Endoxifen's Role
The poster presentation, titled "Anti-cancer Activity of (Z)-Endoxifen-Related Compounds in ER?+ Breast Cancer," showcases research that aims to enhance therapeutic efficacy in treating estrogen receptor alpha-positive breast cancer. By modifying the chemistry of (Z)-endoxifen, Atossa aims to boost the treatment's potency while ensuring better tolerability for patients.
Innovative Poster Presentation Details
This fascinating research delves into how alterations to (Z)-endoxifen can optimize its performance against breast cancer. The poster will detail the strategies used to refine the structure of the compound, with the goal of increasing its effectiveness in targeting cancer cells.
Event Information
Those interested can attend the presentation on Tuesday, December 10, from 6:30 PM to 8:00 PM ET at the Hilton Toronto. This opportunity allows attendees to gain insights into the latest advancements in breast cancer therapies.
About (Z)-Endoxifen
(Z)-endoxifen has established itself as a potent Selective Estrogen Receptor Modulator (SERM), known for its effectiveness in inhibiting estrogen receptors and facilitating their degradation. Its efficacy extends to patients whose tumors have developed resistance to traditional hormonal treatments. Notably, (Z)-endoxifen also functions to target PKC?1, a protein associated with oncogenesis—all while presenting lower risks of adverse effects typically seen with standard therapies.
Proprietary Development by Atossa
Recognizing the significant challenges posed by stomach acid in drug absorption, Atossa is developing a unique oral formulation of (Z)-endoxifen that avoids metabolic breakdown in the liver. This innovative delivery method allows the medication to reach the bloodstream in its active form more efficiently. Early clinical studies indicate that this formulation maintains a strong tolerance profile among participants.
About Atossa Therapeutics
Founded with a commitment to transforming cancer treatment, Atossa Therapeutics focuses on addressing critical unmet medical needs in oncology, particularly in breast cancer. Their dedication is evident in the multiple Phase 2 trials currently underway, which include studies involving women at various stages of breast cancer. The company also possesses strong intellectual property protections with several issued U.S. patents related to (Z)-endoxifen.
Contact Information
Interested parties can reach out to Michael Parks, VP of Investor and Public Relations, at 484-356-7105. For more information about Atossa’s innovative advancements in oncology, visit their official website.
Frequently Asked Questions
What will Atossa present at the AACR conference?
Atossa will present their research on the anti-cancer activity of (Z)-endoxifen and its related compounds in treating ER?+ breast cancer.
When and where is the AACR conference taking place?
The conference is scheduled for December 9-11 at the Hilton Toronto.
Why is (Z)-endoxifen significant?
(Z)-endoxifen is a powerful SERM with potential benefits for patients resistant to conventional treatments, offering enhanced efficacy and safety.
What is Atossa Therapeutics' mission?
Atossa aims to develop groundbreaking therapies for breast cancer and other unmet medical needs in oncology, focusing on innovative drug solutions.
How can I learn more about Atossa Therapeutics?
For comprehensive details regarding their research and clinical trials, please visit Atossa’s official website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.